血清miRNA-135与PSA联合检测对前列腺癌的诊断价值及与临床特征、预后的关系  

Diagnostic value of combined detection of serum miRNA-135 and PSA in prostate cancer and its relationship with clinical characteristics and prognosis

作　　者：彭扬洋 邱樊[1] 王刚 PENG Yangyang;QIU Fan;WANG Gang(Department of Nuclear Medicine,Nanjing Hospital Affiliated to Nanjing Medical University(Nanjing First Hospital),Nanjing 210017,Jiangsu,China;Department of Surgery,Liaoyang Ninth People’s Hospital,Liaoyang 111000,Liaoning,China)

机构地区：[1]南京医科大学附属南京医院(南京市第一医院)南京临床核医学中心,南京210017 [2]辽宁省辽阳市第九人民医院外科,辽宁辽阳111000

出　　处：《癌症进展》2020年第1期69-72,共4页Oncology Progress

摘　　要：目的探讨血清miRNA-135在前列腺癌中的表达情况,并分析其与前列腺特异性抗原(PSA)联合检测对前列腺癌的诊断价值及与临床特征、预后的关系。方法选取108例前列腺癌患者、62例前列腺良性病变患者和40例男性健康体检者作为研究对象,分别命名为前列腺癌组、良性病变组和健康对照组。检测血清miRNA-135及PSA水平;对前列腺癌患者随访3年,记录生存情况。比较各组血清miRNA-135和PSA差异,分析血清miRNA-135与PSA的关系,同时绘制二者在前列腺癌诊断中的受试者工作特征(ROC)曲线,并分析其与临床特征及预后的关系。结果前列腺癌组血清miRNA-135和PSA水平均高于良性病变组和健康对照组,良性病变组血清miRNA-135和PSA水平均高于健康对照组,差异均有统计学意义(P﹤0.05)。血清miRNA-135和PSA呈正相关(P﹤0.05)。绘制ROC曲线,miRNA-135联合PSA检测诊断前列腺癌的曲线下面积为0.981(95%CI:0.901~1.000,P=0.000),截断值为15.34和67.62,灵敏度和特异度分别为90.2%和98.6%。在108例前列腺癌患者中,68例为高表达者,40例为低表达者;不同Gleason评分、分化程度、TNM分期及有无淋巴结转移患者的血清miRNA-135表达情况比较,差异均有统计学意义(P﹤0.05)。随访3年,miRNA-135高表达者生存率低于miRNA-135低表达者(P=0.026);miRNA-135高表达者生存时间明显短于miRNA-135低表达者(P=0.000)。结论血清miRNA-135在前列腺癌中呈高表达,有一定诊断价值,联合PSA可提高其诊断效能,且有望成为临床特征评估及预后预测的有效指标。Objective To evaluate the expression of serum miRNA-135 in prostate cancer,and to analyze the diagnostic value of miRNA-135 combined with prostate specific antigen(PSA)in detecting prostate cancer,so as to determine the relationship with clinical characteristics and prognosis.Method Altogether,108 patients with prostate cancer,62 patients with benign prostatic hyperplasia and 40 healthy males were included in the study as prostate cancer group,benign lesion group and healthy control group,respectively.The serum level of miRNA-135 and PSA in each group were detected;Patients were followed up for 3 years after discharge to assess their survival.The difference between serum levels of miRNA-135 and PSA was identified to analyze their relationship,meanwhile the receiver operating characteristic(ROC)curve was plotted,and the association with clinical characteristics and prognosis was also examined.Result The serum levels of miRNA-135 and PSA in prostate cancer group were higher than those in benign lesion group and healthy control group,besides,those in benign lesion group were higher than that in healthy control group,and the differences were of statistical significance(P<0.05).Serum miRNA-135 was positively correlated with PSA(P<0.05).The ROC curve showed that the area under the curve(AUC)for miRNA-135 combined with PSA was 0.981(95%CI:0.901-1.000,P=0.000),the cut-off values were 15.34 and 67.62,with the sensitivity and specificity being 90.2%and 98.6%,respectively.Among the 108 cases of prostate cancer,68 cases were with high expression and 40 cases were with low expression;Gleason score,differentiation degree,TNM stage and lymph node metastasis were associated with the serum miRNA-135 level in these patients(P<0.05).After 3-year follow-up,the survival rate of high miRNA-135 expression group was significantly lower than that of low expression group(P=0.026);while the survival time was shorter for high expression group compared with low expression group(P=0.000).Conclusion Serum miRNA-135 is highly expressed in prost

关 键 词：前列腺癌 miRNA-135 前列腺特异性抗原 受试者工作特征曲线 临床特征 预后 

分 类 号：R737.25[医药卫生—肿瘤]